Bio Rad Laboratories Inc Stock Research

Market Summary

USD488.28+10.28

Delayed

2.15%

BIO Alerts

Big jump in Earnings (Y/Y)

BIO Stock Price

BIO RSI Chart

BIO Valuation

Market Cap

14.5B

Price/Earnings (Trailing)

-4

Price/Sales (Trailing)

5.18

EV/EBITDA

-3.27

Price/Free Cashflow

177.78

BIO Price/Sales (Trailing)

BIO Profitability

EBT Margin

-167.87%

Return on Equity

-37.73%

Return on Assets

-26.87%

Free Cashflow Yield

0.56%

BIO Fundamentals

BIO Revenue

Revenue (TTM)

2.8B

Revenue Y/Y

-0.34%

Revenue Q/Q

7.27%

BIO Earnings

Earnings (TTM)

-3.6B

Earnings Y/Y

152.65%

Earnings Q/Q

608.42%

Price Action

52 Week Range

344.63607.54

(Low)(High)

Last 7 days

-0.6%

Last 30 days

1.3%

Last 90 days

13.7%

Trailing 12 Months

-12.9%

BIO Financial Health

Current Ratio

5.55

Debt/Equity

0.12

Debt/Cashflow

0.16

BIO Investor Care

Buy Backs (1Y)

0.27%

Diluted EPS (TTM)

-121.25

Peers (Alternatives to Bio Rad Laboratories)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
A	40.4B	6.8B	-13.31%	3.22%	32.19	5.89	8.37%	3.64%
ILMN	35.5B	4.6B	5.65%	-27.02%	-8.07	7.75	1.28%	-677.95%
MTD	32.5B	3.9B	-7.42%	9.05%	37.3	8.3	5.43%	13.46%
WAT	18.2B	3.0B	-10.97%	-4.88%	25.66	6.11	6.68%	2.15%
PKI	15.9B	3.3B	-11.65%	-27.44%	27.98	4.81	-34.64%	-39.65%
MID-CAP
SMALL-CAP
PACB	2.0B	128.3M	-11.70%	-1.09%	-6.37	15.61	-1.69%	-73.40%
ADPT	1.2B	185.3M	-5.41%	-23.53%	-6	6.49	20.06%	3.42%
QTRX	450.3M	105.5M	-12.44%	-50.56%	-4.66	4.27	-4.55%	-67.63%
NSTG	405.5M	127.3M	-23.43%	-69.17%	-2.54	3.19	-12.28%	-38.43%
BNGO	341.8M	27.8M	-23.57%	-31.43%	-2.58	12.29	54.62%	-83.06%
CDXS	271.1M	138.6M	-29.13%	-76.08%	-8.07	1.96	32.30%	-57.86%
PSNL	135.5M	65.0M	-20.46%	-63.49%	-1.2	2.08	-23.92%	-73.73%
HBIO	117.4M	113.3M	-15.92%	-55.18%	-12.34	1.04	-4.68%	-3204.17%
CSBR	54.2M	54.1M	-0.24%	-45.98%	502.17	1	21.80%	-72.38%

Financials for Bio Rad Laboratories

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-0.1%	2,802,300,000	2,804,800,000	2,871,000,000	2,895,800,000	2,922,500,000
Gross Profit	-0.2%	1,567,300,000	1,570,100,000	1,634,000,000	1,640,100,000	1,638,000,000
S&GA Expenses	-1.3%	827,825,000	839,043,000	844,146,000	848,841,000	877,100,000
R&D Expenses	-0.6%	256,889,000	258,342,000	252,874,000	249,231,000	260,600,000
EBITDA	40.2%	-4,666,186,000	-7,803,373,000	-2,594,173,000	-224,902,000	5,439,651,000
EBITDA Margin	40.1%	-1.67	-2.78	-0.08	1.86	-
Earnings Before Taxes	39.9%	-4,704,300,000	-7,830,168,000	-2,598,800,000	-219,100,000	5,449,100,000
EBT Margin	39.9%	-1.68	-2.79	-0.08	1.86	-
Interest Expenses	42.2%	38,114,000	26,795,000	15,558,000	5,201,000	1,551,000
Net Income	39.8%	-3,627,500,000	-6,027,400,000	-1,935,000,000	-93,100,000	4,254,200,000
Net Income Margin	39.8%	-1.29	-2.15	-0.03	1.45	-
Free Cahsflow	-46.1%	81,665,000	151,523,000	363,791,000	459,081,000	535,718,000

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	12.0%	13,502	12,058	12,682	14,374	17,799
Current Assets	0.6%	3,158	3,140	3,250	3,303	1,990
Cash Equivalents	-16.2%	434	518	597	802	471
Inventory	4.9%	719	686	657	605	572
Net PPE	-2.5%	499	512	-	-	-
Goodwill	1.7%	407	400	347	346	347
Liabilities	7.8%	3,886	3,605	3,760	4,191	4,114
Current Liabilities	-0.3%	569	571	614	648	681
Long Term Debt	11291.6%	1,198	11.00	-	-	-
LT Debt, Non Current	0.0%	1,197	1,197	1,197	11.00	-
Shareholder's Equity	13.7%	9,615	8,454	8,923	10,183	13,685
Retained Earnings	9.4%	9,898	9,047	9,210	10,138	13,525
Additional Paid-In Capital	3.9%	447	431	472	459	442
Accumulated Depreciation	0.8%	1,009	1,002	-	-	-
Shares Outstanding	-0.2%	30.00	30.00	30.00	-	-

* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-29.3%	194	275	498	602	670
Cashflow From Investing	29.2%	-1,207	-1,705	-1,702	-1,661	-797
Cashflow From Financing	-8.6%	974	1,065	1,058	1,182	-55.43
Buy Backs	72.5%	216	125	125	0.00	50.00

Risks for BIO

What is the probability of a big loss on BIO?

58.5%

Probability that Bio Rad Laboratories stock will be more than 20% underwater in next one year

34.6%

Probability that Bio Rad Laboratories stock will be more than 30% underwater in next one year.

15.4%

Probability that Bio Rad Laboratories stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BIO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bio Rad Laboratories was unfortunately bought at previous high price.

Drawdowns

Returns for BIO

Cumulative Returns on BIO

14.5%

10-Year Cumulative Returns

20.0%

7-Year Cumulative Returns

12.7%

5-Year Cumulative Returns

11.2%

3-Year Cumulative Returns

What are the long-term rolling returns for BIO?

FIve years rolling returns for Bio Rad Laboratories.

Annualized Returns

Which funds bought or sold BIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-10	MATHER GROUP, LLC.	new	-	217,393	217,393	-%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	added	35.51	1,202,530	4,484,530	-%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-8.34	-23,000	276,000	-%
2023-02-28	Voya Investment Management LLC	reduced	-2.73	-64,841	3,225,160	-%
2023-02-24	SRS Capital Advisors, Inc.	new	-	2,943	2,943	-%
2023-02-24	National Pension Service	unchanged	-	4,944	923,817	-%
2023-02-24	NATIXIS	reduced	-29.68	-172,612	418,388	-%
2023-02-22	TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY	unchanged	-	102,000	12,874,000	0.14%
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	added	39.32	19,116	68,116	-%
2023-02-21	MACQUARIE GROUP LTD	unchanged	-	6,943	946,943	-%

Latest Funds Activity

Are funds buying BIO calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own BIO

No. of Funds

BIO Alerts

Big jump in Earnings (Y/Y)

Bio Rad Laboratories News

Schedule 13G FIlings of Bio Rad Laboratories

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.66%	2,391,436	SC 13G/A
Feb 01, 2023	blackrock inc.	6.4%	1,582,313	SC 13G/A
Apr 11, 2022	schwartz alice n	89.7%	4,555,452	SC 13D/A
Feb 09, 2022	vanguard group inc	9.21%	2,287,465	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 01, 2022	blackrock inc.	7.1%	1,768,081	SC 13G/A
Feb 10, 2021	vanguard group inc	9.18%	2,272,373	SC 13G/A
Feb 08, 2021	fmr llc	-	0	SC 13G
Jan 29, 2021	blackrock inc.	7.6%	1,892,336	SC 13G/A

BIO Fair Value

Bio Rad Laboratories fair value in different scenarios

The table shows the Fair Value estimates for Bio Rad Laboratories for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	- -	- -	- -	- -	- -
Current Inflation	234.47 -51.98%	269.94 -44.72%	384.70 -21.21%	469.38 -3.87%	567.20 16.16%
Very High Inflation	- -	- -	- -	- -	- -

Historical Bio Rad Laboratories Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Bio Rad Laboratories

View All Filings

Date Filed	Form Type	Document
Mar 08, 2023	4	Insider Trading
Feb 23, 2023	8-K	Current Report
Feb 17, 2023	10-K	Annual Report
Feb 16, 2023	8-K	Current Report
Feb 14, 2023	4	Insider Trading
Feb 09, 2023	SC 13G/A	Major Ownership Report
Feb 09, 2023	SC 13G/A	Major Ownership Report
Feb 01, 2023	SC 13G/A	Major Ownership Report
Jan 10, 2023	8-K	Current Report
Dec 19, 2022	4	Insider Trading

About Bio Rad Laboratories

Norman D. Schwartz

www.bio-rad.com

7900

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

BIO Income Statement

2022-12-31

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net sales	$ 730,300	$ 680,800	$ 691,100	$ 700,100	$ 732,800	$ 747,000	$ 715,900	$ 726,800	$ 2,802,249	$ 2,922,545	$ 2,545,626
Cost of Goods and Services Sold									1,234,919	1,284,449	1,107,739
Gross Profit	397,100	372,600	395,000	402,600	399,900	436,500	401,100	400,500	1,567,330	1,638,096	1,437,887
Selling, general and administrative expense									827,825	877,122	798,798
Research and development expense									256,889	260,638	217,763
Income from operations									482,616	500,336	421,326
Interest expense									38,114	1,551	21,861
Foreign exchange losses, net									(205)	2,753	1,771
Debt and Equity Securities, Unrealized Gain (Loss)									5,193,554	(4,926,248)	(4,495,825)
Other (income) expense, net									(44,574)	(26,775)	(24,488)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest									(4,704,273)	5,449,055	4,918,007
Income Tax Expense (Benefit)									1,076,738	(1,194,798)	(1,103,778)
Net Income (Loss) Attributable to Parent	$ 827,700	$ (162,800)	$ (925,100)	$ (3,367,300)	$ (1,572,200)	$ 3,929,600	$ 916,800	$ 980,000	$ (3,627,535)	$ 4,254,257	$ 3,814,229
Basic earnings per share:
Earnings Per Share, Basic	$ 27.89	$ (5.48)	$ (31.05)	$ (112.5)	$ (52.54)	$ 131.80	$ 30.80	$ 32.86	$ (121.79)	$ 142.61	$ 128.13
Weighted average common shares - basic									29,785	29,831	29,768
Diluted earnings per share:
Earnings Per Share, Diluted	$ 27.78	$ (5.48)	$ (31.05)	$ (112.5)	$ (52.54)	$ 130.02	$ 30.41	$ 32.46	$ (121.79)	$ 140.83	$ 126.47
Weighted average common shares - diluted									29,785	30,208	30,160

BIO Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
ASSETS:
Cash and cash equivalents	$ 434,215	$ 470,783
Short-term investments	1,356,457	399,135
Restricted investments	5,560	5,560
Accounts receivable, less allowance for doubtful accounts	494,645	423,537
Inventories:
Total inventories	719,316	572,239
Prepaid expenses	124,179	109,136
Other current assets	23,604	10,089
Total current assets	3,157,976	1,990,479
Property, plant and equipment:
Land and improvements	27,805	27,940
Buildings and leasehold improvements	393,620	385,798
Equipment	1,086,595	1,099,741
Total property, plant and equipment	1,508,020	1,513,479
Less: accumulated depreciation and amortization	(1,009,408)	(1,001,840)
Property, plant and equipment, net	498,612	511,639
Operating Lease, Right-of-Use Asset	180,952	204,798
Goodwill	406,488	347,343
Intangible Assets, Net (Excluding Goodwill)	332,147	253,939
Other investments	8,830,892	14,387,006
Other assets	94,599	104,189
Total assets	13,501,666	17,799,393
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable	135,041	141,941
Accrued payroll and employee benefits	194,790	276,986
Current maturities of long-term debt	465	489
Income taxes payable	11,929	10,319
Accrual for Taxes Other than Income Taxes, Current	20,499	35,980
Current operating lease liabilities	36,336	36,435
Deferred revenue	52,211	50,852
Other current liabilities	117,437	127,936
Total current liabilities	568,708	680,938
Long-term debt, net of current maturities	1,197,716	10,514
Deferred Income Tax Liabilities, Net	1,770,481	3,064,576
Operating lease liabilities	153,597	175,938
Other long-term liabilities	195,912	182,191
Total liabilities	3,886,414	4,114,157
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock	0	0
Additional paid-in capital	447,454	441,733
Retained earnings	9,898,203	13,525,343
Accumulated other comprehensive (loss) income	(466,822)	(175,553)
Stockholders' Equity Attributable to Parent	9,615,252	13,685,236
Total liabilities and stockholders' equity	13,501,666	17,799,393
Common Class A [Member]
Stockholders' equity:
Common stock	2	2
Common Class B [Member]
Stockholders' equity:
Common stock	1	1
Treasury Class-A [Member]
Stockholders' equity:
Treasury Stock, Value	$ (263,586)	$ (106,290)